Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.95 EUR | -1.55% | -6.86% | -0.52% |
06-23 | Hamilton Thorne Maintained at Buy at Stifel GMP on No Impact From U.S. IVF Actions; Price Target Kept at C$2.55 | MT |
05-14 | Hamilton Thorne Q1 Loss Widens Even as Sales Increase | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- The company sustains low margins.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 86.38 times its estimated earnings per share for the ongoing year.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.52% | 162M | - | ||
+2.25% | 211B | B | ||
+5.47% | 185B | B- | ||
+29.54% | 158B | B- | ||
+2.36% | 64.32B | A- | ||
+19.61% | 55.66B | B+ | ||
-1.92% | 48.41B | B+ | ||
-7.89% | 37.82B | A | ||
-0.84% | 35.57B | - | ||
+9.41% | 28.12B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- HTL Stock
- 0ZM Stock
- Ratings Hamilton Thorne Ltd.